Allergan Inc. PharmaVitae Profile

Publication Date	December 2008
Publisher	Datamonitor
Product Type	Report
Pages	86
ISBN Number	not applicable
Product Code	DAT14040

Buy this product or for assistance call +44 20 7060 7474

PDF £3,425.00$5697 | €3833

FAX Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Allergan's performance against key rivals in the prescription pharmaceutical sector
Assess how the Botox franchise, which straddles both the cosmetic and pharmaceutical segments, will continue to shape Allergan's commercial performance
Analyse the impact of Allergan's acquisition of Esprit Pharma in 2007, namely its movement into the urology therapy market

Content

CHAPTER 1 ABOUT THIS PROFILE
- Executive summary
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
- Sales data
- Analyst consensus
CHAPTER 2 EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales performance, 2001-13
- Allergan: PharmaVitae forecasts at a glance
- Strategic insight
- Allergan is highly dependent upon sales of Botox
- Botox plays a central role in Allergan's synergistic expansion
- SWOT analysis
CHAPTER 3 QUARTERLY NEWS UPDATE
- Deals and alliances
- Product deals
- Technology deals
- M&A activity
- Company announcements
- Future product milestones
CHAPTER 4 COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A history
- Acquired by SmithKline Beckman
- Allergan Spun-out from SmithKline Beckman
- Acquisition of Oculinum
- Divestment of Allergan Humphrey
- Divestment of contact lens businesses
- Five acquisitions were made in and around 1995
- Allergan Specialty Therapeutics (ASTI) spun-out
- Allergan Specialty Therapeutics (ASTI) re-acquired
- Bardeen Sciences set-up
- Advanced Medical Optics (AMO) spun-out
- Bardeen Sciences acquired
- Oculex acquired
- Acquistition of Inamed
- Groupe Corneal Laboratoires acquired
- EndoArt acquired
- Agreement to acquire Esprit Pharma
- Current corporate structure
- Pharmaceuticals
- Allergan Medical
CHAPTER 5 COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2001-13
- PRODUCT ANALYSIS
- Product analysis, 2001-07
- Product analysis, 2007-13
- Therapy area analysis
- Therapy area analysis, 2001-07
- Therapy area analysis, 2007-13
- Therapy area focus, 2001-13
- Geographic analysis
- Geographic analysis, 2001-07
- Geographic analysis, 2007-13
- Geographic focus, 2001-13
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2007-13
- Core analysis, 2007-13
- Expiry analysis, 2007-13
- Launch/core/expiry configuration, 2007-13
- Molecule type analysis
- Molecule type analysis, 2001-07
- Molecule type analysis, 2007-13
- Externalization analysis
- Externalization analysis, 2001-07
- Externalization analysis, 2007-13
CHAPTER 6 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Opthalmology
- Alphagan franchise
- Overview
- Sales forecast
- Restasis
- Overview
- Sales forecast
- Lumigan franchise
- Overview
- Sales forecast
- Posurdex
- Overview
- Sales forecast
- Posurdex offers significant benefits over the standard of care
- CNS
- Botox
- Overview
- Sales forecast
CHAPTER 7 APPENDIX
- Abbreviations
- Exchange rates
- Table 1: Allergan - PharmaVitae forecasts at a glance
- Table 2: Allergan product deals and alliances, Q1 2008
- Table 3: Allergan technology deals and alliances, Q1-3 2008
- Table 4: Allergan M&A activity, Q1-3 2008
- Table 5: Allergan company announcements, Q1-3 2008
- Table 6: Allergan future product milestones, 2008-10
- Table 7: Allergan product portfolio overview ($m), 2001-07
- Table 8: Allergan product portfolio overview ($m), 2007-13
- Table 9: Allergan product portfolio overview ($m), 2001-07
- Table 10: Allergan product portfolio overview ($m), 2007-13
- Table 11: Allergan portfolio overview by geographic region ($m), 2001-07
- Table 12: Allergan portfolio overview by geographic region ($m), 2007-13
- Table 13: Allergan launch portfolio overview ($m), 2007-13
- Table 14: Allergan core portfolio overview ($m), 2007-13
- Table 15: Allergan expiry portfolio overview ($m), 2007-13
- Table 16: Allergan portfolio overview by molecule type ($m), 2001-07
- Table 17: Allergan product portfolio overview by molecule type ($m), 2007-13
- Table 18: Allergan product portfolio overview by source ($m), 2001-07
- Table 19: Allergan product portfolio overview by source ($m), 2007-13
- Table 20: Key products overview
- Table 21: Alphagan P: overview
- Table 22: Alphagan franchise: sales forecast ($m), 2007-13
- Table 23: Restasis: overview
- Table 24: Restasis: sales forecast ($m), 2007-13
- Table 25: Lumigan franchise: overview
- Table 26: Lumigan franchise: sales forecast ($m), 2007-13
- Table 27: Posurdex: overview
- Table 28: Posurdex: sales forecast ($m), 2007-13
- Table 29: Botox: overview
- Table 30: Botox: sales forecast ($m), 2007-13
- Table 31: Exchange rates, 2007
List of Figures
- Figure 1: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
- Figure 2: Allergan prescription pharmaceutical sales ($m), 2001-13
- Figure 3: The central role of Botox in Allergan's strategic moves
- Figure 4: Allergan SWOT analysis
- Figure 5: TypeFigTitleHere
- Figure 6: Current corporate structure
- Figure 7: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
- Figure 8: Allergan key sales growth driver & resistors ($m), 2001-07
- Figure 9: Allergan key sales growth drivers & resistors ($m), 2007-13
- Figure 10: Allergan prescription pharmaceutical sales by therapy area ($m), 2001-13
- Figure 11: Allergan prescription pharma sales by therapy area (% of total), 2001-13
- Figure 12: Allergan prescription pharmaceutical sales by geographic region ($m), 2001-13
- Figure 13: Allergan growth drivers and resistors by geographic region ($m), 2001-07
- Figure 14: Allergan drivers and resistors by geographic region ($m), 2007-13
- Figure 15: Allergan prescription pharmaceutical sales by geographic region (% of total), 2001-13
- Figure 16: Allergan launch/core/expiry configuration ($m), 2007-13
- Figure 17: Allergan prescription pharmaceutical sales by molecule type ($m), 2001-13
- Figure 18: Allergan growth drivers and resistors by molecule type ($m), 2007-13
- Figure 19: Allergan prescription pharmaceutical sales by source ($m), 2001-13
- Figure 20: Allergan growth drivers and resistors by source ($m), 2007-13
- Figure 21: Mechanisms by which current treatments reduce intraocular pressure